

## **Global Access Program Providing innovative diagnostics solutions** to those who need it most



#### Universal access to quality healthcare and medical innovation remains a global challenge.

As a community we have an ambitious goal: to stop as many diseases as possible.

Roche continues to partner with national governments, local healthcare facilities, communities and international agencies to go beyond providing diagnostics tests.







S The Global Fund

The Roche Global Access Program provides access to diagnostics for HIV, hepatitis, tuberculosis and cervical cancer in high disease burden and qualified countries where reliable diagnostic solutions are needed most.



# **Global Access Program Timeline**

2014 Announced Global Access Program for HIV viral load testing

2018 Launch of cobas<sup>®</sup> simplify sample collection and transportation and increase access to HIV monitoring testing

> 2021 Expansion of the Global Access Program to include molecular PCR diagnostic tests for COVID-19

# 2016-2017

Expansion to include Early Infant Diagnosis and additional **cobas**° Systems family

2019 Expansion of the Global Access Program to include access to diagnostics for tuberculosis, hepatitis, and cervical cancer

#### **DISEASE PREVALENCE: DEATHS**

#### Hep

In 2021, approximately 650,000 people died due to HIV.<sup>1</sup>

HIV

#### In 2019, hepatitis B resulted in an estimated **820,000** deaths.<sup>2</sup> In 2019,

approximately 290,000 people died from hepatitis C.<sup>3</sup>

ТΒ In 2022,

1.6 million died

from the disease.<sup>4</sup>

# HPV

In 2020, more than 342,000 women died of cervical cancer, about 90% of these deaths occurring in low- and middleincome countries.<sup>4</sup>

COVID-19

In 2020, COVID-19 caused at least **3 million** deaths globally.<sup>10</sup>

### DISEASE ELIMINATION GOALS

### HIV goals by 2030



of people living with HIV will know their HIV status



of people who know their status receive treatment



of treatment on HIV treatment have a suppressed viral load

# Hepatitis goals by 2030<sup>7</sup>



reduction in new cases of chronic hepatitis B and C



reduction in hepatitis B and C



of treatment eligible persons with chronic hepatitis B and C infections

# TB goals by 2030



reduction in the absolute number of TB deaths



reduction in the TB incidence rate



of TB-affected households experiencing catastrophic costs due to TB

# **Cervical cancer goals by 2030**



of girls fully vaccinated with HPV vaccine by 15 years



screened at 35 and 45 years of age and all managed appropriately

of women identified with cervical disease receive treatment for



precancerous lesions or invasive cancer

#### <u>,11</u> VID-19 Elimination Strategy



Increase diagnostic testing for disease surveillance and to prevent initial spread

implement physical distancing measures to decrease rates of transmission



increase awareness, education, and access to vaccinations

#### COUNTRIES WITH GLOBAL ACCESS PROGRAM

The program provides increased access to diagnostics at affordable pricing for qualifying organizations in 82 eligible countries with the highest disease burden.



#### **REFERENCES:**

- 1. https://www.unaids.org/en (accessed 31 May 2023)
- 2. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (accessed 31 May 2023)
- 3. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed 31 May 2023) 4. https://www.who.int/news-room/fact-sheets/detail/tuberculosis (accessed 31 May 2023)
- 5. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer (accessed 31 May 2023)
- 6. Understanding Fast-Track. Accelerating Action to end the AIDS epidemic by 2030.
- https://www.unaids.org/sites/default/files/media\_asset/201506\_JC2743\_Understanding\_FastTrack\_en.pdf (Accessed 29 March 2021) 7. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=AC1645C173756FB7A161689347064065?sequence=1 (accessed 31 May 2023)
- The End TB Strategy 2015. Geneva: World Health Organization; 2015. WHO/HTM/TB/2015.19
- 9. https://cdn.who.int/media/docs/default-source/cervical-cancer/230519-ccei-brochure.pdf?sfvrsn=8f15a050\_5&download=true (accessed 31 May 2023) 10. https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality. (Accessed 31 May 2023)
- 11. Baker MG, Wilson N, Anglemyer A. Successful Elimination of Covid-19 Transmission in New Zealand. N Engl J Med 2020;383:e56. 10.1056/NEJMc2025203

Roche Molecular Systems 4300 Hacienda Drive Pleasanton, CA 94588 USA

https://go.roche.com/Global-Access-Program